Buy Acadia Pharmaceuticals Ahead of FDA Approval said the world's best trader on biotech stocks. See it here live the best market calls and stock forecasts.
Vieira who often calls the absolute top and bottom in stocks on live streaming, urged investors to close their large short positions on Acadia (ACAD) in March 2016 at a price of $17.3
Mr. Vieira has been one of the most bearish investors on Acadia Pharmaceuticals (ACAD) downgrading this biotech company to Junk within the range $48-52, predicting a collapse.
Not only he has the best track record in the world trading biotech stocks as he is the only investor in the world who has been able to accurately predict Acadia (ACAD) trend reversals.
On the following presentation Vieira explained to investors why Acadia (ACAD) is a great buy near $17 with a potential price target range $28-30 - this information was made available on live streaming trading as well as Acadia Stock Forecast 2016.
The stock jumped by as much as 80% after Vieira's upgrade and the San Diego-based company took a big step closer to gaining approval for a key drug in its portfolio.
The drug, called pimavanserin, treats psychosis associated with Parkinson’s disease, and has the potential to be the first drug approved in the U.S. for this condition.
An advisory panel to the U.S. Food and Drug Administration voted 12-2 Tuesday that the benefits of pimavanserin, to be marketed as Nuplazid, outweighed the risks of treatment. The stock was halted all day Tuesday as the panel met, so traders couldn’t speculate on the potential decision in real-time.
The FDA is expected to issue its final decision by May 1. The federal agency isn’t required to follow the advice of its advisory panels. But it generally does so, hence other analysts said they expect the final ruling to go in Acadia’s favor.
Along with that May 1 deadline, the next question for investors will be the requirements for how the product is labeled. Analyst Paul Matteis of Leerink Partners noted that panelists asked for some sort of post-marketing safety requirement, and he said that a so-called “black box” warning is “very likely.”
Such labels contain an explicit warning of potential side-effects within a bold black box.
Acadia Pharmaceuticals (ACAD) shares closed this Friday at $28.66 according to Vieira's forecast shared with investors on live streaming